Page 222 - Remedial Andrology

1063. Montorsi, F., et al. Transdermal electromotive multi-drug administration for Peyronie’s disease:
preliminary results. J Androl, 2000. 21: 85.
https://pubmed.ncbi.nlm.nih.gov/10670523
1064. Di Stasi, S.M., et al. Transdermal electromotive administration of verapamil and dexamethasone for
Peyronie’s disease. BJU Int, 2003. 91: 825.
https://pubmed.ncbi.nlm.nih.gov/12780842
1065. Greenfield, J.M., et al. Verapamil versus saline in electromotive drug administration for Peyronie’s
disease: a double-blind, placebo controlled trial. J Urol, 2007. 177: 972.
https://pubmed.ncbi.nlm.nih.gov/17296390
1066. Twidwell, J., et al. Topical treatment for acute phase Peyronie’s disease utilizing a new gel, H-100: a
randomized, prospective, placebo-controlled pilot study. Int J Impot Res, 2016. 28: 41.
https://pubmed.ncbi.nlm.nih.gov/26700214
1067. Husain, J., et al. Extracorporeal shock wave therapy in the management of Peyronie’s disease: initial
experience. BJU Int, 2000. 86: 466.
https://pubmed.ncbi.nlm.nih.gov/10971273
1068. Liu, T., et al. Cellular signaling pathways modulated by low-intensity extracorporeal shock wave
therapy. Int J Impot Res, 2019. 31: 170.
https://pubmed.ncbi.nlm.nih.gov/30670837
1069. Palmieri, A., et al. A first prospective, randomized, double-blind, placebo-controlled clinical trial
evaluating extracorporeal shock wave therapy for the treatment of Peyronie’s disease. Eur Urol,
2009. 56: 363.
https://pubmed.ncbi.nlm.nih.gov/19473751
1070. Chitale, S., et al. Limited shock wave therapy vs sham treatment in men with Peyronie’s disease:
results of a prospective randomized controlled double-blind trial. BJU Int, 2010. 106: 1352.
https://pubmed.ncbi.nlm.nih.gov/20438568
1071. Palmieri, A., et al. Tadalafil once daily and extracorporeal shock wave therapy in the management
of patients with Peyronie’s disease and erectile dysfunction: results from a prospective randomized
trial. Int J Androl, 2012. 35: 190.
https://pubmed.ncbi.nlm.nih.gov/22085227
1072. Hatzichristodoulou, G., et al. Extracorporeal shock wave therapy in Peyronie’s disease: results of a
placebo-controlled, prospective, randomized, single-blind study. J Sex Med, 2013. 10: 2815.
https://pubmed.ncbi.nlm.nih.gov/23898925
1073. Gao, L., et al. A meta-analysis of extracorporeal shock wave therapy for Peyronie’s disease. Int
J Impot Res, 2016. 28: 161.
https://pubmed.ncbi.nlm.nih.gov/27250868
1074. Gelbard, M. Myofibroblasts and mechanotransduction: do forces in the tunica albuginea contribute
to Peyronie’s disease? J Sex Med, 2008. 5: 2974.
https://pubmed.ncbi.nlm.nih.gov/19090949
1075. Chung, E., et al. Peyronie’s disease and mechanotransduction: an in vitro analysis of the cellular
changes to Peyronie’s disease in a cell-culture strain system. J Sex Med, 2013. 10: 1259.
https://pubmed.ncbi.nlm.nih.gov/23421851
1076. Gontero, P., et al. Use of penile extender device in the treatment of penile curvature as a result of
Peyronie’s disease. Results of a phase II prospective study. J Sex Med, 2009. 6: 558.
https://pubmed.ncbi.nlm.nih.gov/19138361
1077. Levine, L.A., et al. Penile traction therapy for treatment of Peyronie’s disease: a single-center pilot
study. J Sex Med, 2008. 5: 1468.
https://pubmed.ncbi.nlm.nih.gov/18373527
1078. Martinez-Salamanca, J.I., et al. Acute phase Peyronie’s disease management with traction device: a
nonrandomized prospective controlled trial with ultrasound correlation. J Sex Med, 2014. 11: 506.
https://pubmed.ncbi.nlm.nih.gov/24261900
1079. Wymer, K., et al. Comparative Cost-effectiveness of Surgery, Collagenase Clostridium Histolyticum,
and Penile Traction Therapy in Men with Peyronie’s Disease in an Era of Effective Clinical Treatment.
J Sex Med, 2019. 16: 1421.
https://pubmed.ncbi.nlm.nih.gov/31351851
1080. Ziegelmann, M., et al. Outcomes of a Novel Penile Traction Device in Men with Peyronie’s Disease:
A Randomized, Single-Blind, Controlled Trial. J Urol, 2019. 202: 599.
https://pubmed.ncbi.nlm.nih.gov/30916626
1081. Moncada, I., et al. Penile traction therapy with the new device ‘Penimaster PRO’ is effective and safe
in the stable phase of Peyronie’s disease: a controlled multicentre study. BJU Int, 2019. 123: 694.
https://pubmed.ncbi.nlm.nih.gov/30365247

SEXUAL AND REPRODUCTIVE HEALTH - MARCH 2021 221